Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: Brilique (ticagrelor) — AstraZeneca AB
Brilique (ticagrelor) has been authorised for use in the European Union for indications related to Acute Coronary Syndrome and peripheral va…
-
EMA approval · 2026-08-03EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
Authorisation granted for Clopidogrel Zentiva (clopidogrel), expanding or confirming its availability for stroke, peripheral vascular diseas…
-
EMA approval · 2026-06-11EMA Authorised: DuoPlavin (clopidogrel;acetylsalicylic acid) — Sanofi Winthrop Industrie
DuoPlavin, a fixed-dose combination of clopidogrel and acetylsalicylic acid, has been authorised by EMA for acute coronary syndrome and myoc…
-
EMA approval · 2026-03-31EMA Authorised: Brilique (ticagrelor) — AstraZeneca AB
EMA authorised Brilique (ticagrelor) for use in acute coronary syndrome and peripheral vascular disease, with AstraZeneca AB as the marketin…
-
EMA approval · 2026-03-10EMA Authorised: Kengrexal (cangrelor) — Chiesi Farmaceutici S.p.A.
The European Medicines Agency authorised Kengrexal (cangrelor) for acute coronary syndrome and during vascular surgical procedures, with Chi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-02-06FDA Approved: TICAGRELOR — Original Application (Lifestar Pharma LLC)
The FDA approved Lifestar Pharma LLC's original ANDA for ticagrelor, a P2Y12 receptor inhibitor used to reduce thrombotic cardiovascular eve…
-
EMA approval · 2026-02-05EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
The European Medicines Agency authorised Zentiva’s generic clopidogrel product for prevention of stroke, myocardial infarction, acute corona…
-
EMA approval · 2025-11-13EMA Authorised: Efient (prasugrel) — Substipharm
The EMA has authorised Efient (prasugrel) by Substipharm for indications including acute coronary syndrome, unstable angina, and myocardial …
-
EMA approval · 2025-11-05EMA Authorised: Rivaroxaban Viatris (previously Rivaroxaban Mylan) (rivaroxaban) — Viatris Limited
The EMA authorised Viatris Limited to market rivaroxaban (brand name Rivaroxaban Viatris), expanding access to this anticoagulant as a gener…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (BIONPHARMA INC.)
FDA approved an original application for ticagrelor from Bionpharma Inc., making a generic version of this antiplatelet medication available…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Dr. Reddys Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' original application for ticagrelor as a generic version of the antiplatelet drug, expanding access t…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Oryza Pharmaceuticals, Inc.)
FDA approved the ticagrelor product from Oryza Pharmaceuticals, Inc. under its original application (ANDA 208508).
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for a ticagrelor generic.
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods' generic ticagrelor under an original ANDA (ANDA212258), authorizing a generic version of the antiplatelet therapy. Th…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' original Abbreviated New Drug Application for ticagrelor, enabling a generic version of the antiplatel…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Radha Pharmaceuticals INC)
FDA approves Radha Pharmaceuticals INC's original ANDA for Ticagrelor, a generic antiplatelet medication.
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved an Original Application for ticagrelor from Novadoz Pharmaceuticals LLC, indicating the approval of a generic ticagrelor produc…
-
EMA approval · 2025-09-26EMA Authorised: Prasugrel Viatris (previously Prasugrel Mylan) (prasugrel besilate) — Viatris Limited
EMA authorised Prasugrel Viatris (prasugrel besilate) by Viatris Limited; the product is approved for myocardial infarction, acute coronary …
-
EMA approval · 2025-08-28EMA Authorised: Rivaroxaban Accord (rivaroxaban) — Accord Healthcare S.L.U.
The EMA authorised Accord Healthcare's rivaroxaban product (Rivaroxaban Accord) for multiple indications including acute coronary syndrome, …
-
EMA approval · 2025-08-26EMA Authorised: Iscover (clopidogrel) — Sanofi Winthrop Industrie
The European Medicines Agency has authorised Iscover, a clopidogrel product from Sanofi Winthrop Industrie, for preventing thrombotic events…
-
FDA approval · 2025-08-01FDA Approved: CLOPIDOGREL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for clopidogrel from Amneal Pharmaceuticals LLC under the ANDA process (generic product).
-
EMA approval · 2025-07-14EMA Authorised: Plavix (clopidogrel hydrogen sulfate) — Sanofi Winthrop Industrie
The EMA authorised Plavix (clopidogrel hydrogen sulfate) for use with indications including stroke, peripheral vascular disease, atrial fibr…
-
EMA approval · 2025-05-14EMA Authorised: Zyllt (clopidogrel (as hydrogen sulfate)) — Krka, d.d., Novo mesto
EMA authorised Zyllt, a clopidogrel hydrogen sulfate product by Krka, d.d., Novo mesto. It is indicated for preventing vascular events in pa…
-
EMA approval · 2025-05-05EMA Authorised: Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan) (acetylsalicylic acid;clopidogrel hydrogen sulfate) — Mylan Pharmaceuticals Limited
EMA authorised a fixed-dose combination of clopidogrel and acetylsalicylic acid (Viatris) for acute coronary syndrome and myocardial infarct…
-
FDA approval · 2025-05-05FDA Approved: TICAGRELOR — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s original application for ticagrelor, establishing a generic version of the antiplatelet drug. The approval cov…